<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78794">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01730846</url>
  </required_header>
  <id_info>
    <org_study_id>1111009293</org_study_id>
    <secondary_id>R21DA033597</secondary_id>
    <nct_id>NCT01730846</nct_id>
  </id_info>
  <brief_title>Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?</brief_title>
  <official_title>Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether doxazosin will attenuate the ability of
      stress to precipitate smoking lapse behavior in treatment seeking daily smokers.
      Participants will participate in a smoking cessation attempt after the laboratory sessions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Latency (min) to initiate ad-lib smoking session</measure>
    <time_frame>Lab Sessions (Day 20, 22)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Latency to start smoking (min)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of cigarettes smoked during ad-lib session</measure>
    <time_frame>Lab Sessions (Day 20, 22)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of cigarettes smoking during ad-lib session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to first lapse during quit attempt</measure>
    <time_frame>4-wk smoking cessation attempt</time_frame>
    <safety_issue>No</safety_issue>
    <description>Days to first instance of smoking (even a puff)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End of treatment 7-day point prevalence</measure>
    <time_frame>4-wk smoking cessation attempt</time_frame>
    <safety_issue>No</safety_issue>
    <description>Smoking (yes/no) during Week 4 of cessation attempt</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Doxazosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>doxazosin 4mg/day doxazosin 8mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxazosin</intervention_name>
    <description>4 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study.  5-day taper at the end of the study.
8 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.</description>
    <arm_group_label>Doxazosin</arm_group_label>
    <other_name>Cardura</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18-60

          -  Able to read and write English

          -  Smoker

          -  Motivated to Quit Smoking

        Exclusion Criteria:

          -  Any significant current medical conditions that would contraindicate smoking

          -  Current Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) abuse or
             dependence of other substances, other than nicotine dependence or alcohol abuse

          -  Positive test results at intake appointment on urine drug screens for illicit drugs

          -  Past 30 day use of psychoactive drugs including anxiolytics and antidepressants

          -  Women who are pregnant or nursing

          -  Suicidal, homicidal or evidence of current severe mental illness such as
             schizophrenia, bipolar disorder or major depression, or anxiety disorders

          -  Participants who have donated blood within the past 6 weeks

          -  Individuals who are currently taking other medications prescribed for smoking
             cessation

          -  Specific exclusions for administration of doxazosin or any alpha blocker
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherry A McKee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meaghan Lavery</last_name>
    <phone>203-737-2783</phone>
    <email>meaghan.lavery@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale Center for Clinical Investigations, Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meaghan Lavery</last_name>
      <phone>203-737-2783</phone>
      <email>meaghan.lavery@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Sherry A McKee, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>November 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Sherry McKee</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>smoking lapse behavior</keyword>
  <keyword>smoking cessation</keyword>
  <keyword>doxazosin</keyword>
  <keyword>medication effect on smoking lapse behavior</keyword>
  <keyword>medication effect on smoking cessation</keyword>
  <keyword>stress</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Smoking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxazosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
